meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
Diarrhea / Diarrhoea & Irinotecan
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The dose-limiting side effect of the common colon cancer chemotherapeutic Irinotecan is severe Diarrhea / Diarrhoea caused by symbiotic bacterial beta-glucuronidases that reactivate the drug in the gut
Irinotecan-induced diarrhea has been linked to an increase in the expression of colonic beta-glucuronidase, and also increases in beta-glucuronidase-encoding microorganisms.
Irinotecan causes both early and late diarrhea, the latter possibly caused in part by changes in the [gut microbiota](brain://FMSaW_VjYE-eATab2yQVNA/GutMic…
References (Sources)
- Alleviating cancer drug toxicity by inhibiting a bacterial enzyme
- Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
- Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
- Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats